相关实验视频

Updated: Sep 17, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

同时调节TGF-β和GITR通路,促进质瘤中的抗瘤免疫力

Daniela Lorizio¹, Manuela Silginer¹, Julia Friesen¹

¹Department of Neurology and Brain Tumor Center, University Hospital Zurich and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.

Cancer immunology, immunotherapy : CII

|June 28, 2025

概括

结合TGF-β抑制与GITR激素作用,可以增强质母细胞瘤的抗瘤免疫力. 这种双重准策略改善了T细胞活性,增加了瘤细胞的杀死,并促进了小鼠模型的长期存活.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症免疫疗法癌症免疫疗法

背景情况:

质母细胞瘤具有免疫抑制性瘤微环境,阻碍免疫治疗的有效性.
转化生长因子 (TGF) -β信号促进瘤的进展,并抑制T细胞的活动.
葡萄糖皮质体诱导瘤亡因子受体 (GITR) 在质母细胞瘤中的T细胞上高度表达,调节其功能.

研究的目的:

评估结合TGF-β抑制和GITR激动作用在质母细胞瘤小鼠模型中的综合效应.
为了确定这种组合疗法是否可以恢复抗瘤免疫力并改善生存率.

主要方法:

使用了同基因小鼠质瘤模型.
与两种不同的GITR激活剂同时进行TGF-β抑制.
评估了T细胞激活,增殖,细胞因子分泌和瘤细胞杀死在体外和体内.

主要成果:

单靠GITR调节可以增强T细胞的激活和增殖.
与单一治疗相比,组合疗法显著放大了T细胞反应和免疫细胞介导的瘤细胞杀死.
组合治疗改善了存活率,并导致质瘤携带小鼠的长期存活率更高.
幸存的小鼠发展出持久的适应性免疫力,抵抗瘤的重新挑战.

结论:

双重准TGF-β和GITR通路协同增强质母细胞瘤中的抗瘤免疫力.
这种新的组合策略显示出克服免疫治疗局限性的显著临床潜力.
这种方法为持久有效的质母细胞瘤治疗提供了一个有希望的途径.

关键词:

在GITRL中,GITRL是指GITRL.质母细胞瘤 (glioblastoma) 是一个免疫抑制是一种免疫抑制.免疫治疗是一种免疫疗法.微观环境是一个微观环境.

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.